Abstract
Background: A series of perimidinone derivatives (7H-benzo[e]perimidin-7-one) were synthesized and assessed by means of in vitro assays as human MAO inhibitors. These compounds inhibited reversibly the enzymes with inhibitory constants in the range of 2 to 20 μM. In addition, the selectivity of inhibition of the MAO isoforms seems to be significantly dependent of the presence either of heteroatom or electron donating and withdrawing groups on the perimidinone framework, which was verified by using molecular docking simulation with the crystallized MAO receptors. Most of these inhibitors were highly selective: 9 and 11 inhibited selectively the MAO-B isoform while 12 had 10-fold selectivity for MAO-A isoform. Moreover, the compound 12 was both the most selective and potent MAO-A inhibitor among perimidinones.
Result: These results have important implications for the drug design of molecules targeting depression and movement-related disorders.Keywords: Monoamine oxidase (MAO), 7H-benzo[e]perimidin-7-one, Perimidinones, MAO-A, Anti-Parkinson.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:A Medical Approach to the Monoamine Oxidase Inhibition by Using 7Hbenzo[ e]perimidin-7-one Derivatives
Volume: 17 Issue: 4
Author(s): Mitchell Bacho, Eduardo Coelho-Cerqueira, Cristian Follmer, Seyed Mohammad Nabavi, Luca Rastrelli, Eugenio Uriarte and Eduardo Sobarzo-Sanchez
Affiliation:
Keywords: Monoamine oxidase (MAO), 7H-benzo[e]perimidin-7-one, Perimidinones, MAO-A, Anti-Parkinson.
Abstract: Background: A series of perimidinone derivatives (7H-benzo[e]perimidin-7-one) were synthesized and assessed by means of in vitro assays as human MAO inhibitors. These compounds inhibited reversibly the enzymes with inhibitory constants in the range of 2 to 20 μM. In addition, the selectivity of inhibition of the MAO isoforms seems to be significantly dependent of the presence either of heteroatom or electron donating and withdrawing groups on the perimidinone framework, which was verified by using molecular docking simulation with the crystallized MAO receptors. Most of these inhibitors were highly selective: 9 and 11 inhibited selectively the MAO-B isoform while 12 had 10-fold selectivity for MAO-A isoform. Moreover, the compound 12 was both the most selective and potent MAO-A inhibitor among perimidinones.
Result: These results have important implications for the drug design of molecules targeting depression and movement-related disorders.Export Options
About this article
Cite this article as:
Bacho Mitchell, Coelho-Cerqueira Eduardo, Follmer Cristian, Nabavi Mohammad Seyed, Rastrelli Luca, Uriarte Eugenio and Sobarzo-Sanchez Eduardo, A Medical Approach to the Monoamine Oxidase Inhibition by Using 7Hbenzo[ e]perimidin-7-one Derivatives, Current Topics in Medicinal Chemistry 2017; 17 (4) . https://dx.doi.org/10.2174/1568026616666160824120929
DOI https://dx.doi.org/10.2174/1568026616666160824120929 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design
Current Topics in Medicinal Chemistry Lifestyle Modification for Masked Hypertension
Current Hypertension Reviews Hurdles in the Drug Discovery of Cathepsin K Inhibitors
Current Topics in Medicinal Chemistry Preclinical Pharmacokinetics: An Approach Towards Safer and Efficacious Drugs
Current Drug Metabolism Emerging Role of Complement in Ocular Diseases
Current Immunology Reviews (Discontinued) Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Sex Differences in Clinical Outcomes of Patients with Stable Coronary Artery Disease after Percutaneous Coronary Intervention
Current Pharmaceutical Design Stem Cell Gene Therapy for Chronic Renal Failure
Current Gene Therapy Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Some Recent Approaches of Biologically Active Substituted Pyridazine and Phthalazine Drugs
Current Medicinal Chemistry Chymase Inhibitors
Current Pharmaceutical Design Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?
Current Vascular Pharmacology Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future
Current Pharmaceutical Design Vascular Risk Factors and Neurodegeneration in Ageing Related Dementias: Alzheimer’s Disease and Vascular Dementia
Current Alzheimer Research Modulation of Cardiac and Hepatic Cytochrome P450 Enzymes During Heart Failure
Current Drug Metabolism Molecular Damage in Glaucoma: from Anterior to Posterior Eye Segment. The MicroRNA Role
MicroRNA Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews Is the Hepatic Factor a miRNA that Maintains the Integrity of Pulmonary Microvasculature by Inhibiting the Vascular Endothelial Growth Factor?
Current Cardiology Reviews High Throughput Screening for Orphan and Liganded GPCRs
Combinatorial Chemistry & High Throughput Screening